Saturday, November 21, 2026

#Bundibugyo virus disease #outbreak in the #DRC and #Uganda at day 100: an #ESCMID Emerging Infections Subcommittee update

 


Abstract

Background

The 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC) and Uganda has challenged epidemic control despite rapid expansion of response capacity.

Objectives

To reassess the threats identified by the ESCMID Emerging Infections Subcommittee at day 100 and identify clinical and public-health priorities.

Sources

This narrative update draws on published literature and WHO, Africa CDC, ECDC, and national public health reports, using 22 August 2026 as the day-100 analytical cut-off, with data through 20 October for a subsequent update.

Content

By 22 August, the DRC had reported 5514 confirmed cases and 2642 deaths in 57 health zones across six provinces, making it the largest recorded outbreak in the DRC and the second-largest Ebola outbreak by confirmed case count. Uganda contained 20 cases, and its outbreak was declared over on 27 August. By 20 October, the DRC had reported 9704 cases and 4687 deaths in 66 health zones across eight provinces; Kenya had reported nine epidemiologically linked cases and Nigeria one. Contact follow-up improved, but many transmission chains remained unidentified. BDBV-specific diagnostics, therapeutic and post-exposure prophylaxis trials, and vaccine studies expanded, yet no vaccine or virus-specific treatment had demonstrated clinical efficacy. Cross-reactive antibody responses after licensed Ebola vaccination do not establish protection against BDBV. ECDC assessed infection likelihood for EU/EEA residents as very low.

Implications

Epidemic control requires complete contact tracing complemented by active case-finding, earlier referral, high-quality supportive care, health-worker protection, community engagement, flexible financing and preservation of essential health services.


Source: Clinical Microbiology and Infection Journal, https://doi.org/10.1016/j.cmi.2026.10.042

____

#Kazakhstan, #Hospital #queues and high temperatures in #children: What's happening with ARVI in #Almaty? (Kazinform, Nov. 21 '26)

 


Almaty residents are reporting a large number of sick children and long lines at hospital emergency rooms. Doctors attribute the increase to the seasonal increase in acute respiratory viral infections and influenza, reports a Kazinform correspondent.



    One city resident shared a story on the social network Threads about the situation in medical facilities and complained about her child's high fever, which was difficult to bring down.

        "The hospitals are overcrowded! There's a line of 50 people in the emergency room. There are a lot of sick people, especially children. Many have the same symptoms: a high fever of 39-40 degrees Celsius, which is difficult to bring down and then rises again. Our child is also sick. The temperature is 39-40 degrees Celsius, very difficult to bring down, and if it does drop, it doesn't last long. We don't know what to do anymore. What's going on?" wrote an Almaty resident. 

    In the comments, other residents also reported cases of illness among children. Many report similar symptoms—high fever that persists for several days.

        "My child's temperature is 102.4 degrees Fahrenheit and it won't go down. Today I refused hospitalization at the infectious diseases hospital. They said there was a waiting list and too many children," one user shared.

    Some users attribute the increase in the number of cases to the seasonal spread of influenza and acute respiratory viral infections.


Additional beds will be deployed at the hospital

    The Children's City Clinical Infectious Diseases Hospital of Almaty commented on the situation. The medical facility reported a seasonal increase in acute respiratory viral infections and influenza cases and measures to increase its hospital bed capacity.

        "Due to the seasonal increase in acute respiratory viral infections and influenza, the number of hospital beds for children in Almaty is increasing. Medical organizations are taking the necessary measures to ensure access to medical care. There is no reason to panic," the response stated.

    Specifically, the Children's City Clinical Infectious Diseases Hospital plans to deploy 67 additional reserve beds. This will increase the facility's bed capacity from 360 to 427.


25 cases of influenza have been detected in Almaty.

    The Department of Sanitary and Epidemiological Control added that the epidemiological situation in the city remains stable. Despite the annual seasonal increase in acute respiratory viral infections, no exceedance of the control level has been recorded.

        "Since the beginning of the epidemic season, 25 confirmed cases of influenza have been registered. Laboratory monitoring indicates that two types of influenza viruses—A/H1N1 and B—are circulating in the city. Other pathogens causing acute respiratory viral infections are also being identified, including rhinovirus, parainfluenza virus, respiratory syncytial virus, bocavirus, and seasonal coronavirus. No new, unknown viruses have been identified," the department noted.

    The department emphasized that healthcare facilities had prepared in advance for the seasonal increase in cases. Outpatient clinics have established mobile teams to handle house calls, and special filters have been set up to admit patients with symptoms of acute respiratory viral infections and influenza. Infectious disease hospitals have allocated additional beds for the hospitalization of sick patients.

    In addition, flu vaccinations continue in the city. As of November 19, 2026, 251,102 people have been vaccinated, including 248,780 from risk groups.


What do experts recommend?

    The State Sanitary and Epidemiological Survey (DSEC) reminded residents of the need to observe preventative measures during the seasonal increase in cases. Experts recommend regularly washing hands, covering your mouth and nose when coughing and sneezing, wearing masks if you have symptoms, and limiting attendance at public events whenever possible.

    Parents are advised not to send sick children to schools and daycares, and to seek medical attention promptly at the first signs of infection. The department also urged residents not to self-medicate and to take medications only as prescribed by a doctor.

    We previously discussed how to protect yourself from the flu and acute respiratory viral infections during the fall and winter, why it's important to get vaccinated promptly, and what common mistakes to avoid during treatment.


Source: Kazinform, https://www.inform.kz/ru/ocheredi-v-bolnitsah-i-visokaya-temperatura-u-detey-chto-proishodit-s-orvi-v-alm-b0c6edb0

____

#Ebola disease caused by #Bundibugyo virus - #DRC, #Kenya and #Nigeria (WHO D.O.N., Nov. 21 '26)

 


{Excerpts}

Situation at a glance

    Since the publication of the previous Disease Outbreak News on 6 November 2026, additional confirmed cases and deaths have been reported in the Democratic Republic of the Congo. 

    While some areas have seen a slight decline in cases, sustained, high-level transmission continues overall in the country. 

    As of 17 November 2026, a total of 11 613 confirmed cases, including 5678 deaths (crude case fatality ratio: 48.9%), have been reported across 68 health zones in eight provinces, with active transmission ongoing in 48 health zones. 

    Ituri and Nord Kivu remain the most affected provinces, while Sud-Kivu and Sud Ubangi have not reported cases for more than 42 days. 

    The high proportion of deaths occurring in communities, meaning outside of dedicated treatment centres, especially among young children, continues to highlight challenges in early case detection and timely access to appropriate care. 

    Of the 720 deaths reported since 28 October (last three weeks), 452 occurred in communities and 268 in treatment centres. 

    Since the last Disease Outbreak News, no new cases have been reported from Kenya or Nigeria; and no new country has reported confirmed cases. 

    Both countries have started a 42-day countdown to declare the end of their outbreaks. 

    However, the high-level transmission in the Democratic Republic of the Congo calls for continued need for readiness in the region, including cross-border surveillance, points of entry monitoring, timely case detection and coordinated preparedness and response measures. 

    Six months into the outbreak of Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo, the response has expanded significantly, but further scale up is needed, with rising insecurity remaining the greatest obstacle to the expansion of operations. 

    The next phase must prioritize quality, reach and community trust, alongside sustained funding, coordination and security to save lives and end the outbreak. 

On 18 November 2026, the Director-General of WHO, concurring with the advice of the IHR Emergency Committee formulated at its third meeting, on 17 November 2026, determined that the event continues to constitute a public health emergency of international concern (PHEIC). 

    Updated recommendations to the government of the Democratic Republic of the Congo and all other States Parties will be issued in the coming days.


Description of the situation

    Cases have been reported in five countries since the declaration of the outbreak on 15 May 2026: the Democratic Republic of the Congo, France, Kenya, Nigeria, and Uganda. 

    The outbreaks in France and Uganda have been controlled since August, while Kenya and Nigeria continue with heightened surveillance as they count down to 42 days, completing two maximum incubation periods since the last confirmed cases were either discharged or medically evacuated from the country.

    On 26 October 2026, Switzerland reported the medical evacuation of the case, who received medical care in Geneva, Switzerland. 

    The patient recovered and was discharged on 11 November testing PCR-negative for Bundibugyo virus for a second time.

    On 18 November 2026, the United Kingdom of Great Britain and Northern Ireland reported that a medically evacuated health and care worker from the Democratic Republic of the Congo had recovered and been discharged from hospital.


Democratic Republic of the Congo

    An additional 945 confirmed cases, including 480 confirmed deaths, have been reported in the Democratic Republic of the Congo since the previous Disease Outbreak News was published.

    In the last 21-day period, as of 17 November, 1417 new confirmed cases were reported, with Ituri accounting for 668 (13% decrease) cases, Nord Kivu for 635 (8% increase) cases, Haut-Uélé for 90 (13% increase) cases, Tshopo for 20 (47% decrease) cases and Nord-Ubangi for four cases. No new cases were reported in Bas-Uélé, Sud Kivu or Sud-Ubangi during that period.

    As of 17 November, cumulative confirmed cases have reached 11 613, including 5678 deaths and 3148 recoveries. The overall crude CFR is 48.9%.

    Confirmed cases have now been identified in 68 health zones across eight provinces. Forty-eight of the 68 affected health zones reported at least one new case during the preceding 21 days, while 20 reported no recent cases. 

    Beni, Bunia, and Mandima have reported the highest number of cases and deaths in the preceding 21 days. Ituri remains the most extensively affected province, with 28 of 36 health zones reporting cases during this outbreak, followed by Nord Kivu (17/34), Haut-Uélé (8/13), Tshopo (7/23), Bas-Uélé (4/11), Nord-Ubangi (2/11), Sud Kivu (1/34) and Sud-Ubangi (1/16). Watsa in Haut-Uélé province is the most recently affected health zone, reporting 11 confirmed cases.

    Six months into the BVD outbreak, the response has expanded significantly, but transmission remains persistent and geographically widespread. WHO, the national Government and partners have strengthened surveillance, treatment, laboratory capacity and community engagement, yet high community mortality, insecurity, displacement and a fragile health system continue to undermine progress.

    The next phase will need to focus on scaling up, but also on improving the reach, quality and impact of the response. Early detection, quality care, contact tracing, infection prevention and community trust remain critical. Sustained funding, strong coordination and safe access to communities will be essential.

    The third International Health Regulations (IHR) Emergency Committee meeting regarding the epidemic of BVD in the Democratic Republic of the Congo took place on 17 November. Following the advice of the Committee, the Director-General agreed that the ongoing outbreak remains a PHEIC. Updated recommendations to the government of the DRC and all other States Parties will be issued in the coming days and reported in the next Disease Outbreak News publication.  

(...)

    While Nord Kivu reported the highest number of cases in the last seven days (235 cases (40% increase compared to the previous seven days) as of 17 November), Ituri remains the most affected province since the outbreak was declared, with 7946 cumulative confirmed cases and 3751 deaths, with CFR of 47%. Nord Kivu follows with 2996 confirmed cases and 1654 deaths, and continues to record the highest provincial CFR, at 55%. 

    Haut-Uélé has reported 534 cases and 231 deaths, while Tshopo has recorded 109 cases and 35 deaths. The less-affected provinces continue to report substantially fewer cases, but transmission persists in several of them. The continued occurrence of cases across multiple provinces shows that the outbreak remains geographically active even as intensity varies between health zones. Sud-Kivu and Sud Ubangi have not reported cases for more than 42 days.

    As of 17 November 2026, the average proportion of contacts seen daily over the previous 14-day period is 81%, remaining below the required threshold of 95% for a daily average of the proportion of contacts seen over the previous 14-day period. Two provinces were at or above the 95% threshold: Bas-Uele (100%, 56/56) and Nord-Ubangi (99%, 140/138) Five provinces were below the threshold: Haut-Uélé (86%; 1741/1495), Ituri (86% (9564/11 104), Nord-Kivu (77%; 16 015/12 313), Tshopo (68%; 720/526), and Sud-Ubangi (63%; 127/80). Strengthened contact follow-up is required, particularly in provinces below the target, to achieve the minimum threshold of 95%.

(...)


Kenya

    As of 17 November 2026, the cumulative confirmed cases reported in Kenya are nine, including two deaths, with a crude CFR of 22.2%. All eight secondary cases were epidemiologically linked to the imported index case and associated with one cluster (four family members of the index case and four health and care workers).  All seven hospitalized cases have recovered and been discharged (the last case was discharged on 11 November). A 42-day countdown is underway and includes heightened surveillance.

    There is currently no evidence of transmission outside this cluster, and there have been no new confirmed cases since 19 October 2026.  Additionally, all eight secondary cases were already under quarantine as known contacts when they developed symptoms.  

    As of 17 November, of the 135 cumulative contacts identified since the first confirmed case, eight subsequently became confirmed cases and nine contacts left Kenya (relevant National IHR Focal Points were notified). All have completed the 21-day follow-up on 11 November 2026.

(...)


Nigeria

    On 20 October 2026, Nigeria reported one laboratory-confirmed imported case of BVD in the Federal Capital Territory Abuja. On 26 October 2026, Switzerland reported the medical evacuation of the case, who received medical care in Geneva, Switzerland. The patient recovered and was discharged on 11 November, following two PCR-negative test results for Bundibugyo virus.

    As of 13 November, a cumulative of 62 contacts had been identified in Nigeria for follow-up and all the contacts have completed the 21-day follow-up period. National authorities, with support from WHO and partners, have intensified contact tracing, case investigation and infection prevention and control measures, including the provision of essential supplies and personal protective equipment for health workers. Investigations are ongoing to establish the likely source of infection and reconstruct the travel and exposure history of the imported case. WHO has urged countries across the region to strengthen surveillance, laboratory diagnostic capacity, rapid response readiness and cross-border preparedness to mitigate the risk of further transmission.

(...)

Citable reference: World Health Organization (20 November 2026). Disease Outbreak News; Bundibugyo Virus Disease in the Democratic Republic of the Congo, Kenya and Nigeria. Available at:  https://www/who.int/emergencies/disease-outbreak.news.item/2026-DON630 


Source: World Health Organization, https://www/who.int/emergencies/disease-outbreak.news.item/2026-DON630

____

History of Mass Transportation: The BREL Class 87 022 Electric Locomotive working in Bulgaria

 


{Click on Image to Enlarge}

___

By Spookywestie - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/wiki/Special:Redirect/page/83872207


Source: Wikipedia, https://en.wikipedia.org/wiki/British_Rail_Class_87

____

Friday, November 20, 2026

#Portugal - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) ( #poultry ) - Immediate notification

 


{Extract}

(...)

A Poultry Farm in the Santarém Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8014

____

#UK - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) ( #poultry ) - Immediate notification

 


{Extract}

(...)

{Northern Ireland}

    Over 23k, 40 week-old layer hens. Positive test for HPAI H5N1, clinical signs presented prior to testing.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8010

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, Nov. 20 '26)

 


{Extract}

(...)

A(H5) detections in the past week

Time Period: November 08, 2026 - November 14, 2026

    -- A(H5) Detection: 15 site(s) (3.2%)

    -- No Detection: 456 site(s) (96.8%)

    -- No samples: 146 site(s)


{Click on Image to Enlarge}

___

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#USA, #H5 Avian #Influenza: Current #Situation (CDC, Nov. 20 '26): One New Human Case in #Oregon

 


{Extract}

(...)

National situation summary since 2024

    ° Person-to-person spread: None

        § There is no known person-to-person spread at this time.

    ° Current public health risk: Low

        § The current public health risk is Low.

    ° Cases in the U.S.: 75 cases {+1 in Oregon}

    ° Deaths in U.S.: 3 deaths {0}

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/situation-summary/?CDC_AAref_Val=https://www.cdc.gov/flu/avianflu/avian-flu-summary.htm

____

#USA, One New Confirmed #Human Case of Infection with #H5N1 Avian #Influenza Virus in #Oregon (CDC, Nov. 20 '26)

 


{Extract}

(...)

Novel Influenza A Virus Infections

    ° One confirmed human infection with influenza A(H5) virus was reported to CDC this week. 

        § To date, human-to-human transmission of influenza A(H5) virus has not been identified in the United States.

    ° The case was reported by the Oregon Health Authority and occurred in a worker aged ≥18 years at a commercial dairy cattle farm where highly pathogenic avian influenza (HPAI) A(H5) virus has been detected in cows. 

        § This individual developed eye irritation during the week ending November 15, 2026 (Week 45), which they reported to the local health department. 

        § Specimens were collected from the individual and tested at the state public health laboratory where a conjunctival specimen tested presumptive positive for influenza A(H5) virus using the CDC influenza A(H5) assay. 

        § Influenza A(H5) virus was confirmed at CDC. This is the first influenza A(H5) case associated with a dairy worker in Oregon.

    ° There has been a total of four influenza A(H5) cases in dairy workers reported in 2026.

    ° Notification to WHO of this case was completed per International Health Regulations (IHR). More information regarding IHR can be found at http://www.who.int/topics/international_health_regulations/en/.

    ° The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf.

    ° An up-to-date human case summary during the 2024 outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

    ° Information about avian influenza is available at https://www.cdc.gov/bird-flu/.

    ° Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.

    ° The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html

____

#USA, Weekly #US #Influenza #Surveillance Report: Key Updates for Week 45, ending November 14, 2026 (CDC, summary)

 


{Summary}

(...)

Key Points

    ° Multiple seasonal influenza surveillance indicators continue to increase nationally.

    ° Many surveillance indicators are higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater severity overall.

    ° During Week 45 (the week ending November 14, 2026), of the 613 influenza viruses reported by public health laboratories, 608 were influenza A and 5 were influenza B. Of the 365 influenza A viruses subtyped, 352 (96.4%) were influenza A(H1N1)pdm09, 12 (3.3%) were A(H3N2), and 1 (0.3%) was A(H5).

    ° Since Week 21 (the week ending May 30, 2026), 84.8% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been HA subclade E (newly designated alias of D.3.1.1).

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have circulated globally since. Influenza viruses are constantly changing, often requiring updates to influenza vaccines every season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. This week, recently  circulating influenza A(H1N1)pdm09 viruses which were previously designated D.3.1.1 HA subclade  have been reclassified into subclade E (with newly designated HA subclades E.1 to E.4), each with different combinations of genetic changes in their HA genes.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season. So far, almost all the influenza viruses collected and antigenically characterized in the U.S. since Week 21 are antigenically similar to their respective influenza vaccine reference viruses based on CDC laboratory assays.

    ° Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of seven deaths this season.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and all age groups. The severity assessment for the season changes with flu activity.

    ° CDC estimates that there have been at least 3,700,000 illnesses, 50,000 hospitalizations, and 2,800 deaths associated with flu so far this season.

    ° CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 9,200 to 36,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.7% to 7.6%.

    ° Annual seasonal flu vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now. Influenza vaccination coverage estimates and influenza vaccine doses distributed for this season are available in FluVaxView.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1

    ° One confirmed human case of avian influenza A(H5) virus infection was reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html

____

#Poland - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Extract}

(...)

Three Wild Mute Swans in the Zachodniopomorskie Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8009

____

#Korea (Rep. of) - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Exract}

(...)

A wild bird of unspecified species in the Jeollanam-do Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8006

____

#Australia, #H5 avian #influenza events in #wildlife (Dept. of Agriculture, Nov. 20 '26)



{Extract}

(...)

Event data

    As of 4pm AEST, 19 November 2026, Australia has 745 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 344 in South Australia (SA)

        § 86 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 249 in Victoria (VIC)

        § 53 in Tasmania (TAS)^

        § 1 in Other Territories#

    {^} Includes events on Macquarie Island

    {#} Jervis Bay Territory (Commonwealth jurisdiction)

(...)


Source: Australian Department of Agriculture, https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Thursday, November 19, 2026

#USA, #Oregon Health Agency confirms state’s first #human case of avian #influenza #H5 virus of 2026 (Nov. 19 '26)

 


November 19, 2026


H5 bird flu found in individual linked to Morrow County dairy farm


PORTLAND, Ore. – Oregon Health Authority has confirmed the state’s first human case of highly pathogenic avian influenza (HPAI) of 2026. 

    The individual’s infection is linked to an outbreak among cattle at a Morrow County dairy farm.

    Epidemiologists at OHA’s Public Health Division received confirmation of the human HPAI case from the Oregon State Public Health Laboratory on Nov. 18. 

    They have been working closely with the Oregon Department of Agriculture (ODA) and Morrow County Public Health on the outbreak. 

    ODA provides PPE and training in its use to affected farm workers during an outbreak, while public health monitors exposed individuals.

    After developing mild symptoms of HPAI, the affected individual was promptly treated with the antiviral medicine oseltamivir and tested. 

    They did not require hospitalization. 

    Morrow County public health officials have also offered oseltamivir to members of the individual’s household out of an abundance of caution.

    The virus is not known to spread human-to-human. 

    Risk to the public is extremely low.

        “This is not cause for alarm. Rather, it is evidence that the surveillance and response system we have in place is working,” said Melissa Sutton, M.D., medical director for respiratory viral pathogens at OHA. 

        “Our goal is to ensure that all symptomatic farm workers receive prompt testing and treatment to prevent severe disease. We appreciate the partnership with individuals on the farm during this challenging time.”

    While the seasonal flu vaccine does not protect against HPAI, getting the seasonal flu vaccine can help reduce the risk of getting sick with human influenza viruses, which can, in turn, reduce the risk of co-infection with both a human seasonal virus and an avian virus, according to the Centers for Disease Control and Prevention (CDC).

    In Oregon, public health has monitored more than 300 people exposed to sick animals since 2022; one human case of bird flu was identified in 2024 associated with a commercial poultry outbreak.


###


Source: US State of Oregon Department of Health, https://www.oregon.gov/oha/ERD/Pages/OHA-confirms-states-first-human-case-of-avian-influenza-of-2026-11.19.2026.aspx

____

Respiratory #Virus #Activity — #USA, July 2025–June 2026

 


Abstract

Respiratory viral illnesses are common and can lead to severe outcomes, including hospitalization and death. U.S. trends in respiratory virus activity during July 2025–June 2026 were analyzed using data from six complementary public health surveillance systems. Respiratory syncytial virus (RSV) activity occurred unusually late in most U.S. regions. SARS-CoV-2 circulated nationally with typical bimodal peaks that occurred in August 2025 and January 2026. Annual RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged <12 months (790.2; 95% CI = 757.9–825.3), followed by children aged 12–23 months (611.9; 95% CI = 586.3–639.8) and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7). Annual RSV rates overall and by age group did not exceed those observed during 2022–2025. COVID-19–associated hospitalization rates were highest among adults aged ≥75 years (361.2), infants aged <6 months (173.3), and adults aged 65–74 years (111.4). Newly established 2025–2026 national pediatric mortality surveillance provisionally identified 34 RSV-associated pediatric deaths from 35 reporting jurisdictions and 31 COVID-19–associated pediatric deaths from 43 reporting jurisdictions. RSV sequencing did not identify variant substitutions associated with reduced susceptibility to the available RSV monoclonal antibodies for infants. Most SARS-CoV-2 lineages were JN.1 descendants, but detections of BA.3.2, a highly divergent SARS-CoV-2 variant, increased. Circulation of other respiratory viruses followed usual historical patterns. Staying current with recommended RSV and COVID-19 vaccinations reduces the risk for severe illness and disease caused by these viruses.


Source: Morbidity and Mortality Weekly Report Journal, http://dx.doi.org/10.15585/mmwr.mm7545a2

____

Autochthonous #dengue #outbreak spreading from a holiday site to #visitors’ places of residence, #Tuscany, #Italy, August to October 2026

 


Abstract

Between August and October 2026, 49 autochthonous dengue cases were notified in Italy. Of these, 42 were exposed at a Tuscan coastal holiday site, and diagnosed after returning home, in 14 municipalities across seven provinces. Seven additional cases were identified, six in two areas where viraemic cases returned home and one near the holiday site. Dengue virus serotype 2, lineage 2II_F.1.1.5, was identified. When exposure occurs at holiday destinations, investigation and vector control should extend to places where cases reside.


© Creative Commons License. This work is licensed under a Creative Commons Attribution 4.0 International License.


Source: Eurosurveillance Journal, https://doi.org/10.2807/1560-7917.ES.2026.31.46.2600909

____

Structure-guided #design of a dual-antigen #mRNA #vaccine conferring broad protection against #Henipaviruses

 


Abstract

Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are zoonotic paramyxoviruses with high case fatality rates and pandemic potential. Despite their threat, no licensed vaccines are currently available for human use. Here, we present a structure-guided mRNA vaccine strategy that overcomes key challenges in antigen stability, fusogenicity, and cross-protective efficacy. Using rationally engineered NiV F glycoproteins stabilized in the prefusion conformation, we identify a lead candidate (F-205) that abolishes syncytium formation and elicits high prefusion-specific antibody titers. Through systematic combinatorial screening, we determine that co-delivery of F-205 (NiV-M) and G (NiV-B) antigens via mRNA–lipid nanoparticles induces potent neutralizing and cellular immune responses. In stringent golden hamster challenge models, this vaccine confers complete survival against lethal NiV-M, NiV-B and HeV challenge, with viral RNA undetectable in lung, spleen and brain after NiV challenge and significantly reduced viral burden after HeV challenge. We also introduce surrogate assays to assess F conformation and fusion activity under standard biosafety conditions, enabling iterative antigen optimization without live-virus handling. This study defines a broadly protective, mechanistically informed vaccine platform for HNVs and provides a generalizable framework for rational design of mRNA vaccines targeting class I fusion viruses.


Source: Nature Communications, https://doi.org/10.1038/s41467-026-79459-9

____

Assessment of #Ebola virus #persistence in vitreous fluid of Ebola virus disease #survivors with vitreoretinal disease in Sierra Leone: a cross-sectional study

 




Summary

Background

Uveitis is a known ocular manifestation in individuals who have survived Ebola virus disease (EVD). However, whether Ebola virus (EBOV; Orthoebolavirus zairense) persistence in vitreous fluid contributes to long-term sequelae of uveitis in EVD survivors remains unclear. We aimed to characterise the clinical findings and molecular and immunological findings in vitreous fluid from EVD survivors undergoing vitreoretinal surgery.

Methods

This cross-sectional study recruited EVD survivors (cohort 1), household close contacts of EVD survivors (cohort 2), and non-EVD patients with uveitis (cohort 3) from the Sierra Leone Ministry of Health’s Department of Ophthalmology or from the ongoing Sierra Leone Ministry of Health and the Lowell and Ruth Gess Eye Hospital Ebola Survivor Study (SMILE Study). EVD survivor status was based on an Ebola treatment unit certificate and confirmation in the Sierra Leone Association of Ebola Survivors registry, as well as an anti-EBOV assay. Close contacts of EVD survivors were individuals who lived in the same household as patients with EVD during the acute stage of the disease. Non-EVD patients with uveitis were individuals with vitreoretinal disease indications who were anticipated to benefit from surgical intervention. All patients had a comprehensive ophthalmic examination and pars plana vitrectomy with collection of vitreous fluid. These samples were investigated for molecular detection of EBOV RNA via quantitative RT-PCR (qRT-PCR) and evaluation of Goldmann–Witmer coefficients (GWCs) to identify intraocular production of EBOV-binding antibodies. Statistical analyses were performed to compare basic ophthalmic variables, demographic data, and GWC between the three groups.

Findings

From Jan 1, 2023, to Jan 1, 2024, a total of 25 patients (cohort 1 n=10, cohort 2 n=5, cohort 3 n=10) were enrolled. 13 (52%) patients were female, and median age was 39 years (IQR 34·0–53·5). The median time from EVD symptom onset to surgery was 108·5 months (IQR 103·8–110·8) in cohort 1, and the median time from close contact with a patient with EVD to surgery was 106·0 months (IQR 103·0–106·0) in cohort 2. EBOV RNA was detected by qRT-PCR in the vitreous fluid of two (20%) of ten EVD survivors. GWCs for EBOV glycoprotein IgG were significantly elevated (median 3·59, IQR 0·93–12·53, p<0·005 for between-group comparisons) in EVD survivors compared with those in close contacts (median 0, IQR 0–2·2) and patients with uveitis (median 0, IQR 0–0·62).

Interpretation

The detection of virus-specific immune responses and viral RNA at a median of 9 years after EVD diagnosis suggests long-term EBOV RNA persistence in the vitreous fluid of EVD survivors with vitreoretinal disease.

Funding

National Eye Institute of the National Institutes of Health, National Cancer Institute, National Institutes of Health, and Australian National Health and Medical Research Council.


Source: The Lancet Microbe, https://doi.org/10.1016/j.lanmic.2026.101547

____

Wednesday, November 18, 2026

#Bundibugyo Virus Disease #Outbreak, #DRC, #Kenya & #Nigeria - Weekly Report No. 27, Data as of 15 Nov. '26 (WHO, summary): 11,432 cases & 5,593 deaths in DRC

 


{Summary}


{Click on Image to Enlarge}

___

Event description

    The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic  of the Congo continues at a high and sustained level of transmission. 

    During epidemiological week 46 (9 – 15 November 2026), 442 confirmed  cases and 239 confirmed deaths were reported, compared with 458 cases and 228 deaths in week 45; the national seven-day average has remained between 62 and  65 cases per day, and a new health zone, Watsa in Haut-Uélé, reported  its first confirmed cases. 

    Over three epidemiological weeks (weeks 44 – 46 compared with weeks 41  – 43), reported cases decreased by 6.7% and deaths by 4.6%, with a  decline in Ituri partly offset by continued intense transmission in Nord-Kivu, where  Beni remains the health zone with the most cases, and by rising incidence  in Mangala, Mambasa and Mutwanga. 

    Deaths in treatment centres increased in week 46 and the proportion of  deaths occurring in the community fell to 59% (142 of 239), its lowest weekly  level since August. 

    In Kenya, the last patient was discharged on 11 November, and all  contacts have completed their follow-up; the 42-day countdown is under way, and  the event has not yet been declared over. 

    In Nigeria, all 62 contacts completed their 21-day follow-up on 13  November and no secondary case was identified; surveillance continues in both countries. 

    Additionally, Nigeria started the 42 days countdown on 27 Oct after the  case was medically evacuated to Switzerland on the 26 October 2026.

    In the Democratic Republic of the Congo, insecurity in Beni, Mabalako  and Bafwasende, strikes over unpaid salaries in several provinces and community  resistance to safe burials continue to constrain surveillance and response  operations.


Democratic Republic of the Congo

    As of 15 November 2026, the BVD outbreak in the Democratic Republic of  the Congo has affected 68 health zones and 248 health areas across eight provinces. 

    One new health zone, Watsa in Haut-Uélé, was affected during the  reporting period (two confirmed cases reported on 11 November and seven on 13  November). 

    Since External Situation Report #26, (data as of 7 November), an  additional 512 confirmed cases and 270 confirmed deaths have been reported  between 8 and 15 November, of which 442 cases and 239 deaths during epidemiological week 46 (9 – 15 November). 

    The cumulative total is 11 432 confirmed cases, including 5 593 confirmed deaths [crude case fatality ratio (CFR) 48.9%].

    Among cases with a documented outcome (5 593 deaths and 3 109  recoveries), the case fatality ratio is 64.3%; the outcome of the remaining 2 730  cases is still pending or not yet recorded. 

    Transmission remains highly heterogeneous across affected areas. Ituri  continues to account for the largest proportion of cumulative confirmed cases  (68.9%) and accounted for 227 of the 442 cases reported in week 46 (51.4%),  while Nord-Kivu (25.3% of cumulative cases; CFR 55.4%) accounted for 169  (38.2%). Transmission persists at lower levels in Haut-Uélé (35 cases; 7.9%),  Tshopo (10; 2.3%) and Nord-Ubangi (one case).

    National daily incidence rose steadily from May to its highest levels in late July and mid-August, declined through late September and has fluctuated at  a high plateau since early October. The seven-day moving average ranged  between 62 and 65 confirmed cases per day during week 46 (63.1 on 15  November, compared with 65.4 on 8 November), well below the mid-August peak  of 94 but with no downward trend over the last six weeks. Provincial trends diverged. 

    Ituri reported 227 cases in week 46 compared with 223 in week 45 (seven- day average of 32 cases per day on 15 November), with Mandima, Bunia, Mangala  and Mambasa reporting the most cases, while Nord-Kivu reported 169  cases compared with 202 (24 cases per day on 15 November, down from 29 on 8  November), Beni still reporting the largest numbers in the province. 

    Haut-Uélé  reported 35 cases compared with 24 (13 of them on 13 November, seven in the  newly affected Watsa Health Zone), Tshopo 10 compared with six, and Nord- Ubangi one case in Wapinda. Bas-Uélé, Sud-Kivu and SudUbangi have reported no  case in the last 21 days (Figures 1 and 2). 

    By week of symptom onset (Figure  3), confirmed cases recorded in the DHIS2 line list peaked between late July and  mid-August, remained above 400 per week until mid September and have declined gradually since, to 370 in week 43 and 306 in week 44; weeks 44 to 46 are still incomplete because of the delay between symptom onset and reporting (median five days, 90th percentile 14 days).


{Click on Image to Enlarge}

___

(...)


Trend Analysis (21-day comparison):

    During the most recent three epidemiological weeks (weeks 44 – 46, 26  October – 15 November 2026), a total of 1 369 confirmed cases were reported  nationally, compared with 1 468 during the preceding 21 days (weeks 41 – 43, 5 –  25 October), a decrease of 99 cases (−6.7%). 

    Cases in Ituri decreased from 762 to 670 (−12.1%), accounting for 48.9%  of national cases during the latest period, and in Nord-Kivu from 590 to  580 (−1.7%), accounting for 42.4%. Haut-Uélé increased from 77 to 90 cases  (+16.9%; 6.6% of national cases) and Nord-Ubangi from three to four, while  Tshopo decreased from 33 to 25 (−24.2%). Bas-Uélé, which reported three cases in the preceding period, reported none; SudKivu and Sud-Ubangi reported no case in either period. These weekly and three-week figures are sums of the daily counts published in the national sitreps, as on the COUSP dashboard; the  corresponding differences in cumulative counts (1 372 and 1 457 cases) differ  slightly because retrospectively added cases enter the cumulative totals only.

    During the same period, 706 confirmed deaths were reported nationally,  compared with 740 during weeks 41 – 43 (−4.6%). Deaths decreased from 402 to  355 (−11.7%) in Ituri, from 38 to 35 in Haut-Uélé and from 10 to eight in  Tshopo, but increased from 289 to 308 (+6.6%) in Nord-Kivu, which now  accounts for 43.6% of newly reported deaths (39.1% in the preceding period)  against 50.3% for Ituri. Nord-Ubangi, which reported one death in the preceding  period, reported none. In Nord-Kivu, deaths rose while cases fell slightly, consistent with the province's higher case fatality ratio (55.4%).

(...)

    Transmission remained active in more than two-thirds of the health  zones affected since the start of the outbreak. Of the 68 health zones affected to  date, 48 (70.6%) in five provinces reported at least one new confirmed case  during weeks 44 – 46 (26 October – 15 November): 21 in Ituri, 14 in Nord-Kivu,  six in Haut-Uélé, five in Tshopo and two in NordUbangi. The comparison between  the two 21 days periods covers the 54 health zones that reported at least one  case in either period: incidence increased in 22, decreased in 28 and was  unchanged in four (Mahagi and Nyankunde in Ituri, Alimbongo in Nord-Kivu and  Wapinda in Nord-Ubangi); the remaining 14 zones reported no case in either  period.

    The largest absolute increase occurred in Beni, Nord-Kivu (228 to 273  cases; +19.7%), followed by Mutwanga, Nord-Kivu (28 to 71; +153.6%),  Mangala, Ituri (22 to 63; +186.4%), Mambasa, Ituri (46 to 76; +65.2%), Oicha,  Nord-Kivu (43 to 57; +32.6%), Mongbwalu, Ituri (10 to 22), Isiro, Haut-Uélé (7 to  18), Pawa, Haut-Uélé (19 to 29) and Masereka, Nord-Kivu (7 to 16). Watsa in  Haut-Uélé (nine cases), Kilo (five), Drodro and Kambala (one each) in Ituri and  Yakoma in Nord-Ubangi (four) reported cases after none in the preceding period  (Figure 5). Conversely, the largest decreases were observed in Mandima (257 to  202), Rwampara (71 to 48), Bunia (170 to 149), Nia-Nia (27 to 8), Aru (17 to 1)  and Komanda (18 to 2) in Ituri; Butembo (52 to 23), Katwa (61 to 36) and Mabalako (54 to 34) in Nord-Kivu; and Wamba (47 to 23) in HautUélé. In week 46, Beni (71 cases), Mandima (65) and Bunia (51) reported the most cases, followed by Mangala (31), Oicha (25) and Mambasa (24). Zone-level figures are differences in cumulative confirmed cases between SitReps N°143, N°164 and N°185 and reconcile to the national totals.

    There were 20 health zones without a new case during weeks 44 – 46:  Adja, Ariwara, Aungba, Boga, Damas, Gety and Logo in Ituri; Goma, Kayna and  Manguredjipa in Nord-Kivu; Dungu and Gombari in Haut-Uélé; Lubunga and  WanieRukula in Tshopo; Miti-Murhesa in Sud-Kivu; Buta, Dakwa, Ganga and  Viadana in Bas-Uélé; and Bulu in Sud-Ubangi. Six of them (Damas, Gety and Logo  in Ituri, Manguredjipa in Nord-Kivu, and Dakwa and Ganga in Bas-Uélé) had  reported cases during weeks 41 – 43.

(...)

    Weekly confirmed deaths (Figure 7) have fluctuated between 220 and 290  since mid-October: 286 in week 43 (19 – 25 October), 239 in week 44, 228 in  week 45 and 239 in week 46 (9 – 15 November), an increase of 4.8% over the  preceding week. Community deaths decreased from 149 in week 45 to 142 in  week 46 while deaths in treatment facilities rose from 79 to 97, so that the  proportion of deaths occurring in the community fell from 65.4% to 59.4%, the  lowest weekly share since the week of 17 – 23 August (Figure 8). On 15  November, 18 of the 25 confirmed deaths (72%) occurred in the community.  Although the shift in week 46 suggests that more patients reached treatment  facilities before dying, three in five confirmed deaths still occur outside treatment  facilities, and the increase in deaths in treatment centres also points to late presentation.

(...)


Kenya

    Since the previous report, Kenya has reported no new confirmed case of BVD. The cumulative total remains nine confirmed cases, including two deaths  (CFR 22.2%), all belonging to a single chain of transmission linked to the  imported index case; the last confirmed case was reported on 19 October 2026. 

    On 11 November 2026, the Ministry of Health announced the discharge of  the last patient under treatment, the seventh survivor, after two consecutive  negative tests, and the final 11 contacts completed their 21-day monitoring and  were released from quarantine on the same day. For the first time since the first  case was confirmed, Kenya has no patient under treatment and no contact under  follow-up.

    The 42-day countdown started on 12 November 2026; the end of the  event will be declared by the Government if no new case is detected during that  period. Surveillance, screening at points of entry and survivor follow-up continue. 

(...)


Nigeria

    Nigeria has reported a single confirmed case of BVD, confirmed on 20  October 2026 in the Federal Capital Territory, Abuja, in a traveller from Uganda.  The patient was medically evacuated to Switzerland on 26 October and discharged  from the Geneva University Hospitals on 11 November 2026 after full  recovery; the 42-day countdown is counted from 27 October, the day after the  evacuation. No secondary case has been identified. On 13 November 2026, the  Nigeria Centre for Disease Control and Prevention (NCDC) announced that all 62  contacts of the index case had completed their 21-day follow-up; 13 contacts who  developed fever or non-specific symptoms during monitoring tested  negative, as did seven suspected cases reported from Adamawa, Borno, Ekiti, Lagos and Rivers states over the preceding three weeks.

    The 62 contacts include the companion evacuated with the patient,  whose follow-up in Switzerland was due to end on 16 November according to the  Swiss IHR National Focal Point. The Emergency Operations Centre remains  activated and surveillance continues; the completion of contact monitoring does  not constitute a declaration of the end of the event, which will follow WHO criteria.  

    Two lessons stand out from this event: the rapid activation of the incident  management  system and of response activities once the case was notified and  confirmed, and the 12-day interval between symptom onset and notification, eight  days of which were spent in a private health facility, which underlines the  need for a high index of suspicion among clinicians for travellers from affected areas.

(...)


Situation interpretation 

    The BVD outbreak in the Democratic Republic of the Congo remains at a critical juncture six months after its declaration. 

    Transmission is broadly stable at a high level: 442 confirmed cases and 239  deaths were reported in epidemiological week 46, the national seven-day  average has held between 61 and 76 cases per day since the beginning of  October, and the three-week totals fell marginally, from 1 468 to 1 369 cases  (−6.7%) and from 740 to 706 deaths (−4.6%). 

    The decrease is driven by Ituri, where Mandima, Bunia and Rwampara  reported fewer cases, while Mangala and Mambasa in Ituri and Mutwanga and  Oicha in Nord-Kivu are intensifying, Beni remains the largest focus, Haut-Uélé  reported a new health zone (Watsa), and sporadic transmission continued in Tshopo and Nord-Ubangi. 

    The response is still not reaching the performance required to interrupt transmission: only half of investigated suspected cases are isolated within 24  hours, close to one in six contacts is not seen each day, more than 1 000 contacts  have been lost to follow-up, and three in five deaths still occur in the community,  although the share of community deaths fell in week 46 and safe burial refusals  decreased. 

    Insecurity in Beni, Mabalako and Bafwasende, strikes over unpaid  salaries and shortages of vaccine doses in Nord-Kivu further constrain operations. 

    In Kenya, where eight secondary cases occurred in a single chain, all  contacts have completed follow-up and the 42-day countdown is under way; in  Nigeria, contact monitoring 18 ended on 13 November with no secondary case identified. 

    Neither event has been declared over and surveillance continues in both  countries. Priorities remain reinforcing response capacity in the most active health  zones of Nord-Kivu (Beni, Mutwanga, Oicha) and Ituri (Mandima, Bunia,  Mangala, Mambasa), investigating the new focus in Watsa, improving the  timeliness of isolation of suspected cases and the completeness of contact follow- up, maintaining safe burial performance, securing vaccine supply for frontline  workers, and maintaining cross-border surveillance and information sharing.


Source: World Health Organization, Regional Office for Africa, https://www.afro.who.int/countries/kenya/publication/ebola-bundibugyo-virus-disease-outbreak-democratic-republic-congo-uganda-weekly-external-situation

____

My New Space

Most Popular Posts